Drug intelligence / Profile preview

VB23

Development stage: Preclinical
Lead developer: Shenzhen Yangli Pharmaceutical Technology
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics

Overview

VB23 is a small interfering RNA (siRNA) therapeutic candidate under development by Zhejiang Yangli Pharmaceutical Technology (VyBio). It is designed to target undisclosed genetic pathways involved in lipid metabolism and liver pathology for the treatment of dyslipidemia and metabolic dysfunction-associated steatotic liver disease (MASLD). Currently in the discovery phase, VB23 utilizes siRNA-mediated gene silencing to potentially provide a long-acting treatment option within the company's cardiovascular, renal, and metabolic (CVRM) portfolio.

Beyond the preview

Go deeper on VB23.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VB23.

Explore the full profile